Navigation Links
Terumo Cardiovascular Systems Reaches Agreement on Terms of Consent Decree With FDA Regarding Quality System Improvements
Date:3/22/2011

ANN ARBOR, Mich., March 22, 2011 /PRNewswire/ -- Terumo Cardiovascular Systems (Terumo CVS), a U.S.-based subsidiary of Terumo Corporation of Tokyo, Japan, today announced it has agreed to the terms of a consent decree with the U.S. Food & Drug Administration (FDA) regarding quality system improvements at the company's Ann Arbor, Michigan facility.  The agreement will be subject to the approval of the United States District Court for the Eastern District of Michigan.  

The consent decree addresses observations raised by FDA inspectors during audits of quality system processes at the company's Ann Arbor, Michigan plant.  Under the agreement, Terumo CVS will create and execute a work plan to resolve the observations.  Until the work plan is complete, Terumo CVS agrees to restrict the distribution of certain products manufactured at the plant to existing customers who deem the products medically necessary.  Products manufactured at the plant include heart-lung machines and cannulae, and other related products used in cardiac surgery.

Other Terumo CVS products are available without restriction, including:  oxygenators, perfusion circuits that don't contain cannulae, and all other products produced at the company's other manufacturing facilities in Elkton, Maryland and Ashland, Massachusetts; and products distributed by Terumo CVS that are manufactured by other suppliers.  

The consent decree does not involve any other Terumo subsidiary or corporate entity.

Terumo CVS products are safe for use when used in accordance with their Instructions for Use.  The consent decree does not require that the company remove, recall or perform corrective actions on any products in use at customer facilities.  

"Terumo CVS is committed to fully addressing all of the FDA's concerns.  Over the past year, Terumo CVS had already begun implementing a significant quality system initiative that will cre
'/>"/>

SOURCE Terumo Cardiovascular Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
2. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
3. Terumo Heart Summarizes Results of DuraHeart(TM) LVAS Implants
4. Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial
5. Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient
6. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Terumo to Sponsor Presentations on Key Issues in Cardiac and Vascular Surgery at Society of Thoracic Surgeons Annual Meeting
9. Terumo To Simultaneously Evaluate Misago Self-Expanding Stent System in the United States and Japan
10. VirtuoSaph® Plus Endoscopic Vessel Harvesting System from Terumo Continues the Advancement of the Minimally Invasive Technique for Coronary and Peripheral Artery Bypass Grafting
11. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014 WHEN: Wednesday, October 29, ... registration available at: http://bit.ly/1yStiU9 SPEAKERS: ... and Visionary Innovation Research Group Senior Research ... self-assembling materials, nanobots and flexible electronics are ... transform our lives in the coming decades. ...
(Date:10/22/2014)... Conn. , Oct. 22, 2014  Recently published ... have bolstered the already substantial database of evidence. This ... adoption of Stretta therapy for sufferers of ... clinical evidence supporting Stretta therapy as a ... policies that make Stretta therapy available to nearly 50 ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
(Date:10/20/2014)... (PRWEB) October 20, 2014 Allegheny General ... procedure that enables physicians to repair a damaged mitral ... MitraClip system, developed by Abbott Vascular ... a progressive and life-threatening condition in which the heart’s ... to flow backward from the heart’s left ventricle into ...
(Date:10/20/2014)... 2014 ASCNYC (ascnyc.org) is a ... New Yorkers living with HIV/AIDS and other chronic ... recovery and self-sufficiency. Each year, ASCNYC spotlights selected ... through their tireless efforts. , Savills Studley ... has been selected as this year’s honoree for ...
(Date:10/20/2014)... Ga. (PRWEB) October 20, 2014 ... and relationship-marketing firm, announced today that William H. ... named the 2014 ISE® Luminary Leadership Award winner. ... the achievements of an outstanding leader and industry ... and contributions in advancing the information security industry. ...
(Date:10/20/2014)... October 20, 2014 Zereana Jess-Huff, a 34-year-old ... Maryland 2014 on a platform to think outside the bra. ... uses her position to raise awareness about women’s other lady ... breast cancer. You say the color pink and everybody knows ... for a fact that it has not been won when ...
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
Breaking Medicine News(10 mins):Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2
... 1 The boards of directors for ... Care announced today the appointment of,Thomas Lescault ... In Arizona, SCAN offers a health plan ... long-term care services to,individuals enrolled in the ...
... Corporation,(Nasdaq: SMTS ) announced today that its Board ... an additional $15 million of its common,shares (for a ... may be,made from time to time in the open ... amount of, and purposes for, any,purchases will be determined ...
... the first time, researchers have demonstrated that the administration ... or H2S the molecule that gives rotten eggs ... blood loss in rats. , Cell biologist Mark B. ... of Fred Hutchinson Cancer Research Center, in collaboration with ...
... researchers say , , TUESDAY, July 1 (HealthDay News) -- ... by examining characteristics of the first two cases of ... analysis of data on more than 18,200 Dutch patients ... concluded there,s a 56 percent chance of a large ...
... Services,Inc., has been sold to Assurance Investment Partners (AIP). ... in Kentucky, Arison has six,offices across Kentucky and sells ... The company will continue to operate under the ... will be employed by AIP. Paul,Anderson, who served as ...
... the insurer on the annual listing for the ... ... Today Black Enterprise magazine,applauded Aflac,s outstanding achievements in workplace diversity ... Diversity listing.,This recognition highlights the well-branded insurer,s remarkable minority,representation in ...
Cached Medicine News:Health News:SCAN Health Plan Arizona and SCAN Long Term Care Appoints Thomas Lescault President of Arizona Operations 2Health News:Somanetics Announces Share Repurchase Program Increased By $15 Million 2Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 2Health News:'Hibernation-on-demand' drug significantly improves survival after extreme blood loss 3Health News:TB Outbreaks May Be Predicted by First 2 Cases 2Health News:Assurance Investment Partners Purchases Arison Insurance Services from Anthem Blue Cross and Blue Shield 2Health News:Aflac Named as a Top Company for Diversity by Black Enterprise Magazine 2Health News:Aflac Named as a Top Company for Diversity by Black Enterprise Magazine 3
... The Dual Media Set, different from ... Broth (LB) or other specially prepared medium, ... OVEREXPRESSION BROTH (OB). For cell expansion, E. ... the production of the recombinant protein is ...
...
0.3% Beef extract, 0.5% Peptone, 0.5 % Lactose....
... controls the temperature at your lab bench. This ... to 99 C*, with the "plus" being a ... C. The thermoblocks for 0.2 ml**, 0.5 ml, ... a high degree of flexibility for a multitude ...
Medicine Products: